Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns

被引:74
作者
Hodgkins, Paul [1 ]
Setyawan, Juliana [1 ]
Mitra, Debanjali [2 ]
Davis, Keith [2 ]
Quintero, Javier [3 ]
Fridman, Moshe [4 ]
Shaw, Monica [5 ]
Harpin, Valerie [6 ]
机构
[1] Shire Dev LLC, Wayne, PA 19087 USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] Hosp Univ Infanta Leonor, Madrid, Spain
[4] AMF Consulting Inc, Los Angeles, CA USA
[5] Norgine Pharmaceut, Uxbridge, Middx, England
[6] Ryegate Childrens Ctr, Sheffield, S Yorkshire, England
关键词
Attention deficit/hyperactivity disorder; Methylphenidate; Amphetamine; Atomoxetine; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; GUANFACINE EXTENDED-RELEASE; DOUBLE-BLIND; LIFE-SPAN; ADOLESCENTS; TOLERABILITY; EFFICACY;
D O I
10.1007/s00431-013-1969-8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
This study was a retrospective chart review performed to examine and describe physician practice patterns in managing attention deficit/hyperactivity disorder (ADHD) across Europe. Physicians treating ADHD in the UK, France, Germany, Italy, the Netherlands and Spain were recruited. Each physician abstracted medical records of five patients (aged 6-17 years at time of review) with a documented diagnosis of ADHD made between January 2004 and June 2007. Data provided by the physician via the abstraction included (a) physician characteristics, (b) patient characteristics, (c) ADHD diagnosis and (d) ADHD outcomes (adherence, symptom control and satisfaction). A total of 779 patients met study inclusion criteria. In the overall population, patients' mean (SD) age at time of diagnosis was 8.9 (2.6) years. The predominant treatment choice was long-acting methylphenidate, which was prescribed to more than 56 % of patients. According to physicians, only 30.8 % of patients showed 'complete symptom control' on current treatment and only 31.8 % of physicians reported being 'very satisfied' with their patients' current treatment. Physicians' assessments of complete symptom control and physician satisfaction with treatment were low, indicating unmet needs with current ADHD management in Europe.
引用
收藏
页码:895 / 906
页数:12
相关论文
共 26 条
[1]  
Adesman Andrew R., 2001, Prim Care Companion J Clin Psychiatry, V3, P66
[2]  
[Anonymous], 2009, CHILD ADOL PSYCH MEN
[3]  
[Anonymous], 2009, ATT DEF HYP DIS DIAG
[4]  
[Anonymous], 2000, Diagnostic and statistical manual of mental disorders, V4th, P85
[5]   ADHD medication use, adherence, persistence and cost among Texas Medicaid children [J].
Barner, Jamie C. ;
Khoza, Star ;
Oladapo, Abiola .
CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 :13-22
[6]  
Biederman J, 1998, J CLIN PSYCHIAT, V59, P4
[7]  
Biederman J, 1996, ARCH GEN PSYCHIAT, V53, P437
[8]  
BIEDERMAN J, 1991, AM J PSYCHIAT, V148, P564
[9]   A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder [J].
Biederman, Joseph ;
Melmed, Raun D. ;
Patel, Anil ;
McBurnett, Keith ;
Konow, Jennifer ;
Lyne, Andrew ;
Scherer, Noreen .
PEDIATRICS, 2008, 121 (01) :E73-E84
[10]   Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study [J].
Biederman, Joseph ;
Krishnan, Suma ;
Zhang, Yuxin ;
McGough, James J. ;
Findling, Robert L. .
CLINICAL THERAPEUTICS, 2007, 29 (03) :450-463